HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • The HEOR & RWE Marketplace
    • Visit the Market Place
    • On-demand Webinar
  • Industry Events
    • 5 Tips for Trade Show Success
    • HE Innovation Webinar
    • Webinar Services from HealthEconomics.Com
    • View Conferences
    • View Webinars
    • View Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute
You are here: Home / Featured / Praluent Trial Showed Less Benefit than Projected

Praluent Trial Showed Less Benefit than Projected

A key trial released over the weekend of Praluent, the cholesterol-lowering drug developed by Regeneron Pharmaceuticals and Sanofi, likely impacted the recent decision to lower the drug’s price.

The drug, which was originally priced at $14,000 for a year’s treatment, will be priced between $4,500-$8,000, according to the drugmakers.

According to a report on the Chicago Tribune, the trial found the treatments reduced cardiovascular complications by 15 percent, which missed the 20-percent mark market analysts predicted would lead to broader insurance coverage.

“Maybe price before was for an aspiration of benefit that did not materialize,” Yale University Cardiologist and Center for Outcomes Research and Evaluation Director Dr. Harlan Krumholz said. “(The) benefit for this population for the class of drugs seems clearer. Now for the proper pricing. And Coverage.”

Regeneron, according to the Tribune’s report, reached the new price after working with the Institute for Clinical and Economic Review (ICER).

“The drug pricing landscape and companies’ approaches to it is very different that it was a few years ago,” ICER Founder and President Steven Pearson said. “They think true strategic success for the pharmaceutical industry is going to mean that they will have to master value-based pricing.

To read more on the latest move by Regeneron and Sanofi, click here.



You might also be interested in:

  • Using AI, NLP and Data Visualization with RWE to Generate… 06/10/2020
  • ICER Publishes Final Evidence Report on Digital Therapeutics… 12/11/2020
  • New Roadmap Aims to Transform Healthcare Landscape by… 08/13/2020
  • Stanford Center for Health Education Launches Online Program… 08/11/2020
  • Real World Evidence Poised to Tip the Balance in Fight Against… 08/26/2020
  • What Does $11M in Donations to Congress Buy Pharma? 08/12/2020
  • Robert Dubois, MD, PhD, Steps in as Interim President and CEO… 09/01/2020

 

View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Conference of the Week:

Link of the Week:

Job of the Week:

Webinar of the Week:

White Papers

  • Whitepaper: The Role of Centralized Care Management in Value-based Care
  • 2017 In-Depth Outlook on Oncology Report
  • Value-Based Healthcare: Making it Happen
  • Value-Based Contracting for Biopharmaceuticals Moves Forward
  • ICER Releases White Paper on Gene Therapy

Syndicated Reports

  • HTA in Europe: Key Success Factors for Positive HTA Recommendations
  • Paying for Digital Health: Payer Insights
  • Benchmarking Pharma’s MSL Capabilities
  • Biosimilars: US Payer Perspectives
  • KAM Metrics: Driving Efficiency, Measuring Success
HealthEconomics.Com

HealthEconomics.Com

  • News
  • Conferences
  • Reports
  • Jobs
  • Consulting
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools
  • Webinar Services

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • Webinar Services
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HE Institute

Strategy, Training, Education, and Communications in HEOR & Market Access.

Innovation Webinar

Big ideas accelerating change in HEOR, RWE and Health Technology. Learn more!

tHEORetically Speaking Blog

Insights and observations for HEOR, market access, pricing, reimbursement, and health policy.

HE Jobs Portal

Your Premier Employment Source for HEOR, Market Access, and Real World Evidence

HE Webinars

Online educational and informational seminars for HEOR, market access, pricing, and reimbursement.
  • HealthEconomics.Com
  • About HealthEconomics.Com
  • Advertising Inquiries
  • Careers
  • Contact HealthEconomics.Com

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • The HEOR & RWE Marketplace
    • Visit the Market Place
    • On-demand Webinar
  • Industry Events
    • 5 Tips for Trade Show Success
    • HE Innovation Webinar
    • Webinar Services from HealthEconomics.Com
    • View Conferences
    • View Webinars
    • View Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute